Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Nvidia Weighs Expanding H200 AI Chip Production as China Demand Surges 
Coca-Cola’s Proposed Sale of Costa Coffee Faces Uncertainty Amid Price Dispute 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
 Securities Case - EconoTimes)
NEW YORK, Nov. 08, 2016 -- Scott+Scott, Attorneys at Law, LLP (“Scott+Scott”), a national investor rights law firm, reminds investors that January 5, 2017 is the last day to file lead plaintiff papers in the securities lawsuit against Teva Pharmaceutical Industries Limited (“Teva” or the “Company”) (NYSE:TEVA). The class action is on behalf of a class consisting of all persons who purchased Teva American Depositary Shares (“ADSs”) between February 10, 2015 and November 3, 2016, both dates inclusive (the “Class Period”). Teva investors are encouraged to go to: http://www.scott-scott.com/cases/new/securities-fraud-litigation-3027-teva-pharmaceutical-industries-limited-teva.html.
Teva primarily develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines. Teva ADSs are traded on the New York Stock Exchange (“NYSE”) under the ticker symbol “TEVA.”
The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Teva was involved in and/or had been involved in conduct that would result in an antitrust investigation by the U.S. Department of Justice and the State of Connecticut Office of the Attorney General; (2) the DOJ investigation and the misconduct may instigate U.S. prosecutors to file criminal charges against Teva for alleged price manipulation; (3) as a result, Teva lacked effective internal controls; and (4) consequently, Teva's public statements were materially false and misleading at all relevant times.
What You Can Do
If you purchased Teva ADSs, you may have legal claims against the Company. If you want to discuss filing lead plaintiff papers, or have questions about your legal rights, please contact attorney Joseph Pettigrew at (619) 517-1129, or at [email protected].
About Scott + Scott, Attorneys at Law, LLP
Scott+Scott has significant experience prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm has offices in New York, London, Connecticut, California, and Ohio. Please visit www.scott-scott.com for more information about the firm.
CONTACT: Joseph Pettigrew Scott+Scott, Attorneys at Law, LLP (619) 517-1129 [email protected]
